

Lewis R Roberts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1382381/publications.pdf>

Version: 2024-02-01

365
papers

38,066
citations

5876

81
h-index

3476

182
g-index

380
all docs

380
docs citations

380
times ranked

37625
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Prognostic Model Covering All Stages of Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 254-262.	0.7	5
2	Impact of patients' gender on microvascular lower extremity reconstruction. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2022, 56, 47-52.	0.4	1
3	Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. <i>Hepatology Communications</i> , 2022, 6, 223-236.	2.0	8
4	Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	3.6	6
5	Decreasing Trend of Serum α -Fetoprotein Level in Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1177-1179.e4.	2.4	13
6	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 173-182.e7.	2.4	62
7	Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification. <i>Human Pathology</i> , 2022, 119, 15-27.	1.1	6
8	PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and ^{68}Ga -PSMA PET Using Cyclotron-Produced ^{68}Ga . <i>Hepatology Communications</i> , 2022, 6, 1172-1185.	2.0	15
9	Whole-Genome Sequencing Surveillance and Machine Learning of the Electronic Health Record for Enhanced Healthcare Outbreak Detection. <i>Clinical Infectious Diseases</i> , 2022, 75, 476-482.	2.9	42
10	Impact of trimodality sampling on detection of malignant biliary strictures compared with patients with primary sclerosing cholangitis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 884-892.	0.5	10
11	Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 804-810.	1.1	5
12	Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 79-92.	1.5	4
13	Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation. <i>BMC Cancer</i> , 2022, 22, 221.	1.1	4
14	Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults. <i>JAMA Network Open</i> , 2022, 5, e2148599.	2.8	10
15	Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. <i>Hepatology</i> , 2022, 76, 1634-1648.	3.6	10
16	Large Hepatic Adenomas and Hepatic Adenomatosis: A Multicenter Study of Risk Factors, Interventions, and Complications. <i>American Journal of Gastroenterology</i> , 2022, 117, 1089-1096.	0.2	4
17	Impact of Low Rates of Influenza on Next-Season Influenza Infections. <i>American Journal of Preventive Medicine</i> , 2022, 62, 503-510.	1.6	9
18	Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. <i>Digestive and Liver Disease</i> , 2022, 54, 964-972.	0.4	8

#	ARTICLE	IF	CITATIONS
19	Estimating the Impact of Low Influenza Activity in 2020 on Population Immunity and Future Influenza Seasons in the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab607.	0.4	17
20	Understanding the genetic basis for cholangiocarcinoma. <i>Advances in Cancer Research</i> , 2022, , .	1.9	0
21	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	3.6	18
22	310 Transcriptomics for gallbladder cancer prognosis. <i>Journal of Clinical and Translational Science</i> , 2022, 6, 54-54.	0.3	0
23	Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 2120.	1.7	10
24	Unmet Needs in Oncology Clinical Research and Treatment in Africa: Focus on Ghana. <i>Oncologist</i> , 2022, 27, 760-767.	1.9	2
25	A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2597-2605.e4.	2.4	73
26	Method for Economic Evaluation of Bacterial Whole Genome Sequencing Surveillance Compared to Standard of Care in Detecting Hospital Outbreaks. <i>Clinical Infectious Diseases</i> , 2021, 73, e9-e18.	2.9	23
27	Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. <i>Hepatology</i> , 2021, 73, 14-26.	3.6	66
28	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
29	Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkers. <i>American Journal of Transplantation</i> , 2021, 21, 186-197.	2.6	24
30	Impact of Intraoperative Hypothermia on Microsurgical Free Flap Reconstructions. <i>Journal of Reconstructive Microsurgery</i> , 2021, 37, 174-180.	1.0	8
31	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140.	3.6	23
32	Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 207-218.	4.5	22
33	The Difference a Decade Makes. <i>Hepatology</i> , 2021, 73, 1-3.	3.6	3
34	Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	21
35	Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2624-2634.	3.3	10
36	Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. <i>Cell Reports</i> , 2021, 34, 108765.	2.9	25

#	ARTICLE	IF	CITATIONS
37	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. <i>Nature Communications</i> , 2021, 12, 1930.	5.8	7
38	Aspirin and Statin Use and the Risk of Gallbladder Cancer. <i>Cancers</i> , 2021, 13, 1186.	1.7	3
39	Prescriber perspectives on <scp>lowâ€value</scp> prescribing: A qualitative study. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1500-1507.	1.3	7
40	Elevated rates of horizontal gene transfer in the industrialized human microbiome. <i>Cell</i> , 2021, 184, 2053-2067.e18.	13.5	167
41	Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1692-1701.	2.8	9
42	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. <i>Liver Cancer</i> , 2021, 10, 407-418.	4.2	17
43	Distribution and Incidence of Blood-Borne Infection among Blood Donors from Regional Transfusion Centers in Burkina Faso: A Comprehensive Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1577-1581.	0.6	3
44	Differential characteristics and outcomes of Asian and nonâ€Asian patients with HBVâ€related hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 1922-1932.	1.9	15
45	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. <i>Hepatology Communications</i> , 2021, 5, 1448-1459.	2.0	8
46	BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study. <i>Hpb</i> , 2021, 23, 762-769.	0.1	11
47	Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2â€Plateletâ€Derived Growth Factor Receptor Betaâ€Yesâ€Associated Protein Signaling Axis. <i>Hepatology</i> , 2021, 74, 1411-1428.	3.6	10
48	Hepatitis B Screening of At-Risk Immigrants Seen at Primary Care Clinics: A Quality Improvement Project. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 635-644.	1.2	4
49	Distinct Patterns of HBV Integration and TERT Alterations between in Tumor and Non-Tumor Tissue in Patients with Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7056.	1.8	12
50	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240.	1.5	2
51	Using cell-free DNA for HCC surveillance and prognosis. <i>JHEP Reports</i> , 2021, 3, 100304.	2.6	27
52	Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 3235-3248.	3.6	9
53	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2021, 74, 2622-2632.	3.6	31
54	Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 593-605.	4.2	14

#	ARTICLE	IF	CITATIONS
55	Exogene: A performant workflow for detecting viral integrations from paired-end next-generation sequencing data. PLoS ONE, 2021, 16, e0250915.	1.1	3
56	Sulfatase-2 Regulates Liver Fibrosis through the TGF- β 2 Signaling Pathway. Cancers, 2021, 13, 5279.	1.7	7
57	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplantation Direct, 2021, 7, e635.	0.8	4
58	Evaluating the effectiveness of problem-solving courts at preventing fatal and non-fatal opioid events: preliminary findings from Indiana. Drugs in Context, 2021, 10, 1-11.	1.0	1
59	Comparisons in long-term clinical outcomes among patients with upper or lower extremity lymphedema treated with diverse vascularized lymph node transfer. Microsurgery, 2020, 40, 130-136.	0.6	35
60	Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 907-916.	3.6	123
61	Type 3 Inositol 1,4,5-trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma. Hepatology, 2020, 71, 583-599.	3.6	45
62	REPLY:. Hepatology, 2020, 72, 362-363.	3.6	0
63	Reply. Hepatology, 2020, 72, 364-365.	3.6	0
64	Independent and Joint Use of Statins and Metformin by Elderly Patients With Diabetes and Overall Survival Following HCC Diagnosis. Journal of Clinical Gastroenterology, 2020, 54, 468-476.	1.1	9
65	Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma. Hepatology, 2020, 72, 940-948.	3.6	35
66	Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. American Journal of Physiology - Renal Physiology, 2020, 319, G333-G344.	1.6	4
67	Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. Hepatology International, 2020, 14, 776-787.	1.9	15
68	Development of a Synthetic Population Model for Assessing Excess Risk for Cardiovascular Disease Death. JAMA Network Open, 2020, 3, e2015047.	2.8	8
69	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. Cancers, 2020, 12, 2375.	1.7	2
70	Quality of Care in Patients With Cirrhosis: Trends in Recommended Adult Vaccination Coverage. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 667-682.	1.2	4
71	Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Hepatology Communications, 2020, 4, 1781-1792.	2.0	9
72	Age and generational patterns of overdose death risk from opioids and other drugs. Nature Medicine, 2020, 26, 699-704.	15.2	37

#	ARTICLE	IF	CITATIONS
73	Impact of body mass index on long-term surgical outcomes of vascularized lymph node transfer in lymphedema patients. <i>Gland Surgery</i> , 2020, 9, 603-613.	0.5	3
74	Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. <i>Value in Health</i> , 2020, 23, 409-415.	0.1	23
75	The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 619-629.	1.4	7
76	Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine. <i>JHEP Reports</i> , 2020, 2, 100068.	2.6	18
77	Knowledge, Attitudes, and Behaviors of Viral Hepatitis Among Recent African Immigrants in the United States: A Community Based Participatory Research Qualitative Study. <i>Frontiers in Public Health</i> , 2020, 8, 25.	1.3	14
78	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	1.8	164
79	Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma. <i>Journal of Cancer</i> , 2020, 11, 2241-2251.	1.2	1
80	PKC δ Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. <i>Cancer Cell</i> , 2020, 38, 247-262.e11.	7.7	73
81	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
82	Bioimpedance Spectroscopy for Assessment of Breast Cancer-Related Lymphedema: A Systematic Review. <i>Plastic Surgical Nursing</i> , 2020, 40, 86-90.	0.3	7
83	The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex. <i>Journal of Biological Chemistry</i> , 2020, 295, 2698-2712.	1.6	9
84	Prepectoral Two-Stage Implant-Based Breast Reconstruction with and without Acellular Dermal Matrix: Do We See a Difference?. <i>Plastic and Reconstructive Surgery</i> , 2020, 145, 263e-272e.	0.7	41
85	Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2020, 72, 1298-1309.	3.6	15
86	One-carbon metabolism-related micronutrients intake and risk for hepatocellular carcinoma: A prospective cohort study. <i>International Journal of Cancer</i> , 2020, 147, 2075-2090.	2.3	14
87	A global view of hepatocellular carcinoma: trends, risk, prevention and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 589-604.	8.2	2,482
88	Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in Small-Animal Model. <i>Radiology</i> , 2019, 292, 752-759.	3.6	5
89	DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. <i>Clinical Epigenetics</i> , 2019, 11, 145.	1.8	31
90	Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. <i>Theranostics</i> , 2019, 9, 7239-7250.	4.6	59

#	ARTICLE	IF	CITATIONS
91	Induction of Lysosome-associated Protein Transmembrane 4 Beta via Sulfatase 2 Enhances Autophagic Flux in Liver Cancer Cells. <i>Hepatology Communications</i> , 2019, 3, 1520-1543.	2.0	4
92	Forecasted Size of Measles Outbreaks Associated With Vaccination Exemptions for Schoolchildren. <i>JAMA Network Open</i> , 2019, 2, e199768.	2.8	27
93	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
94	Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular clinical analysis and potential targeted approach. <i>Hepatology International</i> , 2019, 13, 490-500.	1.9	36
95	Surgical Management of Lower Extremity Lymphedema: A Comprehensive Review. <i>Indian Journal of Plastic Surgery</i> , 2019, 52, 081-092.	0.2	31
96	Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice. <i>Gastroenterology</i> , 2019, 157, 210-226.e12.	0.6	50
97	Distinct phenotype and function of circulating VÎ1+ and VÎ2+ Î³T-cells in acute and chronic hepatitis B. <i>PLoS Pathogens</i> , 2019, 15, e1007715.	2.1	23
98	Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1432-1438.	0.5	63
99	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Clinical Liver Disease</i> , 2019, 13, 1-1.	1.0	49
100	Genetic features associated with ¹⁸ F-FDG uptake in intrahepatic cholangiocarcinoma. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 153.	0.4	14
101	Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study. <i>Scientific Reports</i> , 2019, 9, 16849.	1.6	17
102	Role of Killer cell immunoglobulin-like receptors (KIR) genes in stages of HIV-1 infection among patients from Burkina Faso. <i>Biomolecular Concepts</i> , 2019, 10, 226-236.	1.0	12
103	Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. <i>Hepatology</i> , 2019, 69, 1180-1192.	3.6	138
104	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. <i>Gastroenterology</i> , 2019, 156, 492-509.	0.6	145
105	Heat Stress and Thermal Ablation Induce Local Expression of Nerve Growth Factor Inducible (VGF) in Hepatocytes and Hepatocellular Carcinoma: Preclinical and Clinical Studies. <i>Gene Expression</i> , 2019, 19, 37-47.	0.5	6
106	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 531-538.	1.1	135
107	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 739-747.e8.	2.4	24
108	Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. <i>Contemporary Clinical Trials</i> , 2019, 76, 49-54.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. <i>Translational Oncology</i> , 2019, 12, 143-153.	1.7	37
110	The incidence rates and survival of gallbladder cancer in the USA. <i>European Journal of Cancer Prevention</i> , 2019, 28, 1-9.	0.6	36
111	Gallbladder cancer: epidemiology and genetic risk associations. <i>Chinese Clinical Oncology</i> , 2019, 8, 31-31.	0.4	89
112	Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma. <i>American Journal of Cancer Research</i> , 2019, 9, 546-561.	1.4	6
113	Current Status of the GALAD and BALAD Biomarker Models for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2019, 15, 672-675.	0.2	2
114	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 68, 723-750.	3.6	3,096
115	Staged surgical treatment of extremity lymphedema with dual gastroepiploic vascularized lymph node transfers followed by suction-assisted lipectomy: A prospective study. <i>Journal of Surgical Oncology</i> , 2018, 117, 1148-1156.	0.8	39
116	Hepatic stellate cell-derived platelet-derived growth factor receptor α -enriched extracellular vesicles promote liver fibrosis in mice through SHP2. <i>Hepatology</i> , 2018, 68, 333-348.	3.6	73
117	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2018, 68, 949-963.	3.6	106
118	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
119	Dynamic Abandon/Extract Decisions for Failed Cardiac Leads. <i>Management Science</i> , 2018, 64, 633-651.	2.4	7
120	AASLD guidelines for the treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 358-380.	3.6	2,932
121	Vascularized appendicular lymph node transfer for treatment of extremity lymphedema: A case report. <i>Microsurgery</i> , 2018, 38, 553-557.	0.6	14
122	Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 115-122.e10.	2.4	21
123	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. <i>Liver International</i> , 2018, 38, 136-143.	1.9	58
124	Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens. <i>Arthritis Care and Research</i> , 2018, 70, 533-541.	1.5	18
125	Venous invasion by hepatic tumors: imaging appearance and implications for management. <i>Abdominal Radiology</i> , 2018, 43, 1947-1967.	1.0	12
126	Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma. <i>International Journal of Hyperthermia</i> , 2018, 34, 812-823.	1.1	14

#	ARTICLE	IF	CITATIONS
127	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , 2018, 68, 78-88.	3.6	45
128	More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 895-902.	1.9	27
129	Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease. <i>Arthritis Care and Research</i> , 2018, 70, 834-841.	1.5	5
130	Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. <i>Modern Pathology</i> , 2018, 31, 141-149.	2.9	47
131	Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. <i>Hepatology</i> , 2018, 67, 401-421.	3.6	329
132	Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. <i>Hepatology</i> , 2018, 67, 2085-2095.	3.6	50
133	Barriers in Hepatitis C Treatment in Somali Patients in the Direct Acting Antiviral Therapy Era. <i>Journal of the National Medical Association</i> , 2018, 110, 556-559.	0.6	3
134	Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. <i>Cancer Medicine</i> , 2018, 7, 5870-5878.	1.3	14
135	Insights into the interplay between KIR gene frequencies and chronic HBV infection in Burkina Faso. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018, 10, e2018060.	0.5	9
136	Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma. <i>Current Hepatology Reports</i> , 2018, 17, 385-391.	0.4	1
137	A model predicting short-term mortality in patients with advanced liver cirrhosis and concomitant infection. <i>Medicine (United States)</i> , 2018, 97, e12758.	0.4	5
138	Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. <i>Science</i> , 2018, 361, .	6.0	416
139	Gastrointestinal and Extra-Intestinal Manifestations of IgG4-Related Disease. <i>Gastroenterology</i> , 2018, 155, 990-1003.e1.	0.6	62
140	Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS [®] -Preference (PROPr) Scoring System. <i>Medical Decision Making</i> , 2018, 38, 683-698.	1.2	92
141	Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. <i>British Journal of Radiology</i> , 2018, 91, 20180345.	1.0	22
142	Using time-varying models to estimate post-transplant survival in pediatric liver transplant recipients. <i>PLoS ONE</i> , 2018, 13, e0198132.	1.1	2
143	HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data. <i>BMC Bioinformatics</i> , 2018, 19, 271.	1.2	14
144	Prevalent hepatitis B surface antigen among first-time blood donors in Gabon. <i>PLoS ONE</i> , 2018, 13, e0194285.	1.1	16

#	ARTICLE	IF	CITATIONS
145	Heat Stress and Hepatic Laser Thermal Ablation Induce Hepatocellular Carcinoma Growth: Role of PI3K/mTOR/AKT Signaling. <i>Radiology</i> , 2018, 288, 730-738.	3.6	19
146	DNA Methylation of Telomere-Related Genes and Cancer Risk. <i>Cancer Prevention Research</i> , 2018, 11, 511-522.	0.7	12
147	Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. <i>World Journal of Gastroenterology</i> , 2018, 24, 1321-1331.	1.4	16
148	Using Health Information Technology to Foster Engagement: Patients's Experiences with an Active Patient Health Record. <i>Health Communication</i> , 2017, 32, 310-319.	1.8	37
149	Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer. <i>Epigenetics</i> , 2017, 12, 215-225.	1.3	23
150	Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. <i>Healthcare</i> , 2017, 5, 105-111.	0.6	5
151	Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 103-111.	3.7	177
152	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
153	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). <i>Targeted Oncology</i> , 2017, 12, 201-209.	1.7	25
154	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	1.1	43
155	Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression. <i>Scientific Reports</i> , 2017, 7, 43864.	1.6	72
156	From Data to Improved Decisions: Operations Research in Healthcare Delivery. <i>Medical Decision Making</i> , 2017, 37, 849-859.	1.2	25
157	Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?. <i>Current Hepatology Reports</i> , 2017, 16, 137-145.	0.4	26
158	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. <i>Liver Cancer</i> , 2017, 6, 126-136.	4.2	23
159	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , 2017, 169, 1327-1341.e23.	13.5	1,794
160	Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 742-748.	1.1	29
161	Identification of fucosylated Fetuin A as a potential biomarker for cholangiocarcinoma. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600141.	0.8	18
162	Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection in South America. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1631-1632.	2.4	22

#	ARTICLE	IF	CITATIONS
163	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , 2017, 186, 356-366.	1.6	15
164	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
165	Microsurgical reconstruction in patients greater than 80 years old. <i>Microsurgery</i> , 2017, 37, 546-551.	0.6	27
166	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 767-775.e3.	2.4	112
167	MR elastography of hepatocellular carcinoma: Correlation of tumor stiffness with histopathology features—Preliminary findings. <i>Magnetic Resonance Imaging</i> , 2017, 37, 41-45.	1.0	59
168	Reply. <i>Hepatology</i> , 2017, 65, 1422-1423.	3.6	0
169	Clinical, Biochemical, and Histopathology Features of Patients With Glycogenic Hepatopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 927-933.	2.4	22
170	To reverse or not to reverse? A systematic review of autograft polarity on functional outcomes following peripheral nerve repair surgery. <i>Microsurgery</i> , 2017, 37, 169-174.	0.6	22
171	Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 540-547.	0.6	27
172	<i>Sleeping Beauty</i> Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. <i>Cancer Research</i> , 2017, 77, 6576-6588.	0.4	40
173	Comparison of long-term clinical outcomes among different vascularized lymph node transfers: 6-year experience of a single center's approach to the treatment of lymphedema. <i>Journal of Surgical Oncology</i> , 2017, 116, 671-682.	0.8	64
174	Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 384-390.	1.1	8
175	Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa — Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 394.	3.7	2
176	High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver. <i>Epigenetics</i> , 2017, 12, 55-69.	1.3	40
177	Cost-Effective Drug Switch Options After Unsuccessful Treatment With an SSRI for Depression. <i>Psychiatric Services</i> , 2017, 68, 81-87.	1.1	5
178	Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. <i>Cancer</i> , 2017, 123, 81-89.	2.0	46
179	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. <i>Hepatology</i> , 2017, 65, 777-788.	3.6	83
180	Transcriptional Induction of Periostin by a Sulfatase 2 — TGF β 1 — SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2017, 77, 632-645.	0.4	50

#	ARTICLE	IF	CITATIONS
181	Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 115-124.	1.2	13
182	Khat chewing and cirrhosis in Somaliland: Case series. <i>African Journal of Primary Health Care and Family Medicine</i> , 2016, 8, e1-4.	0.3	14
183	Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. <i>F1000Research</i> , 2016, 5, 879.	0.8	159
184	Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress. <i>PLoS ONE</i> , 2016, 11, e0162634.	1.1	22
185	Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 859-860.	1.8	123
186	Aspirin use and the risk of cholangiocarcinoma. <i>Hepatology</i> , 2016, 64, 785-796.	3.6	84
187	Statins and metformin for chemoprevention of hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2016, 8, 48-52.	1.0	14
188	Reply. <i>Hepatology</i> , 2016, 64, 2258-2259.	3.6	0
189	Fluorescence in situ hybridization compared with conventional cytology for the diagnosis of malignant biliary tract strictures in Asian patients. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1228-1235.	0.5	32
190	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. <i>Cancer Letters</i> , 2016, 380, 163-173.	3.2	72
191	Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. <i>Hepatology</i> , 2016, 63, 148-158.	3.6	72
192	Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. <i>Journal of Clinical Oncology</i> , 2016, 34, 1898-1904.	0.8	69
193	Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. <i>Journal of Surgical Oncology</i> , 2016, 114, 475-482.	0.8	56
194	p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer. <i>Cancer Cell</i> , 2016, 30, 595-609.	7.7	183
195	Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. <i>American Journal of Gastroenterology</i> , 2016, 111, 1573-1580.	0.2	61
196	In Vivo Changes of Breast Perfusion After Augmentation. <i>Aesthetic Surgery Journal</i> , 2016, 36, 1133-1140.	0.9	2
197	The Next Chapter in Cost-effectiveness Analysis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1049.	3.8	11
198	Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma. <i>Human Mutation</i> , 2016, 37, 1097-1105.	1.1	21

#	ARTICLE	IF	CITATIONS
199	Stories of MDM. <i>Medical Decision Making</i> , 2016, 36, E446-E447.	1.2	0
200	Anti-invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151. <i>International Journal of Oncology</i> , 2016, 49, 2037-2045.	1.4	26
201	A new HIF1 α /RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice. <i>Hepatology</i> , 2016, 63, 1576-1591.	3.6	35
202	Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. <i>Hepatology</i> , 2016, 64, 1442-1450.	3.6	126
203	Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5.	0.6	178
204	Clinical implications of basic research in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, 736-745.	1.8	42
205	Metformin does not improve survival of cholangiocarcinoma patients with diabetes. <i>Hepatology</i> , 2016, 63, 667-668.	3.6	15
206	Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. <i>Oncotarget</i> , 2016, 7, 20080-20092.	0.8	43
207	Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. <i>Chinese Clinical Oncology</i> , 2016, 5, 61-61.	0.4	94
208	Robotic Harvest of a Right Gastroepiploic Lymph Node Flap. <i>Archives of Plastic Surgery</i> , 2016, 43, 210-212.	0.4	23
209	Biomarkers for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2016, 12, 252-5.	0.2	1
210	Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors. <i>Hepatology</i> , 2015, 61, 361-374.	3.6	60
211	Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma. <i>Cancer Medicine</i> , 2015, 4, 1599-1602.	1.3	9
212	Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. <i>Liver International</i> , 2015, 35, 2155-2166.	1.9	813
213	Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. <i>Scientific Reports</i> , 2015, 5, 14752.	1.6	241
214	Integration of extracellular RNA profiling data using metadata, biomedical ontologies and Linked Data technologies. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 27497.	5.5	48
215	HIV Treatment in Resource-Limited Environments: Treatment Coverage and Insights. <i>Value in Health</i> , 2015, 18, 1113-1119.	0.1	1
216	Right gastroepiploic lymph node flap. <i>Microsurgery</i> , 2015, 35, 496-497.	0.6	40

#	ARTICLE	IF	CITATIONS
217	Validation Is Necessary but Insufficient. <i>Medical Decision Making</i> , 2015, 35, 815-816.	1.2	2
218	Targeting an Alcohol Intervention Cost-effectively to Persons Living with HIV/AIDS in East Africa. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 2179-2188.	1.4	8
219	Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 599-606.	1.3	95
220	Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 264-268.	1.0	44
221	Restoration of Epigenetically Silenced Sulfatase 1 Expression by 5-Aza-2-Deoxycytidine Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy-Induced Apoptosis. <i>Medical Epigenetics</i> , 2015, 3, 1-18.	262.3	8
222	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	0.6	109
223	DNAJB1-PRKACA is specific for fibrolamellar carcinoma. <i>Modern Pathology</i> , 2015, 28, 822-829.	2.9	142
224	Screening for Hepatocellular Carcinoma and Cholangiocarcinoma: Can Biomarkers Replace Imaging?. <i>Current Hepatology Reports</i> , 2015, 14, 128-138.	0.4	9
225	Ectopic Gallbladder. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e69.	2.4	5
226	Classification and Staging of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 277-294.	1.0	19
227	Biphenotypic hepatic tumors: imaging findings and review of literature. <i>Abdominal Imaging</i> , 2015, 40, 2293-2305.	2.0	43
228	Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. <i>Annals of Internal Medicine</i> , 2015, 162, 397-406.	2.0	303
229	Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent <i>Clostridium difficile</i> Infection. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 438-444.	1.0	63
230	An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples. <i>Gastroenterology</i> , 2015, 149, 1813-1824.e1.	0.6	113
231	The role of hepatic resection in the treatment of hepatocellular cancer. <i>Hepatology</i> , 2015, 62, 440-451.	3.6	310
232	Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2015, 110, 1629-1631.	0.2	68
233	Prognostic Value of Model for End-Stage Liver Disease Score Measurements on a Daily Basis in Critically Ill Patients With Cirrhosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1196-1206.	1.4	5
234	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 183-192.	2.4	90

#	ARTICLE	IF	CITATIONS
235	Activation of the transforming growth factor β /SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1269-1283.	3.6	47
236	Update on Biomarkers of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 237-245.	2.4	114
237	Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. <i>PLoS ONE</i> , 2014, 9, e92273.	1.1	49
238	The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions. <i>Annals of Internal Medicine</i> , 2014, 161, 170.	2.0	129
239	Heat stress induced cell death mechanisms in hepatocytes and hepatocellular carcinoma: In vitro and in vivo study. <i>Lasers in Surgery and Medicine</i> , 2014, 46, 290-301.	1.1	31
240	Lymph Node Flap Based on the Right Transverse Cervical Artery as a Donor Site for Lymph Node Transfer. <i>Annals of Plastic Surgery</i> , 2014, 73, 398-401.	0.5	59
241	Chemopreventive strategies in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 45-54.	8.2	247
242	Role for Putative Hepatocellular Carcinoma Stem Cell Subpopulations in Biological Response to Incomplete Thermal Ablation: In Vitro and In Vivo Pilot Study. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 1343-1351.	0.9	17
243	Fibroblast growth factor signaling in liver carcinogenesis. <i>Hepatology</i> , 2014, 59, 1166-1173.	3.6	71
244	Liver Masses: A Clinical, Radiologic, and Pathologic Perspective. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1414-1429.	2.4	73
245	A New Clinically Based Staging System for Perihilar Cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2014, 109, 1881-1890.	0.2	80
246	Short and long telomeres increase risk of amnesic mild cognitive impairment. <i>Mechanisms of Ageing and Development</i> , 2014, 141-142, 64-69.	2.2	34
247	Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 87-112.		0
248	Platelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis. <i>Journal of Biological Chemistry</i> , 2014, 289, 22835-22849.	1.6	47
249	Treating Hepatitis C in Lower-Income Countries. <i>New England Journal of Medicine</i> , 2014, 370, 1869-1871.	13.9	70
250	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2014, 45, 1630-1638.	1.1	235
251	Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. <i>Hepatology</i> , 2014, 60, 2008-2016.	3.6	145
252	Twelve-month cost-effectiveness of telephone-delivered collaborative care for treating depression following CABG surgery: a randomized controlled trial. <i>General Hospital Psychiatry</i> , 2014, 36, 453-459.	1.2	44

#	ARTICLE	IF	CITATIONS
253	Rethinking cancer immunotherapy: Using advanced cancer genetics in immune-mediated eradication of gastrointestinal cancers. <i>Hepatology</i> , 2014, 60, 2121-2124.	3.6	4
254	Should Expectations about the Rate of New Antiretroviral Drug Development Impact the Timing of HIV Treatment Initiation and Expectations about Treatment Benefits?. <i>PLoS ONE</i> , 2014, 9, e98354.	1.1	5
255	Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. <i>Oncotarget</i> , 2014, 5, 9425-9443.	0.8	78
256	Metformin does not improve survival in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 15750.	1.4	33
257	Hepatitis C Virus: Pathogenesis and Host Immune Response. , 2014, , 51-86.		0
258	Hepatitis Viruses: Hepatocellular Carcinoma. , 2014, , 785-804.		0
259	AS30D Model of Hepatocellular Carcinoma: Tumorigenicity and Preliminary Characterization by Imaging, Histopathology, and Immunohistochemistry. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 198-203.	0.9	14
260	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013, 45, 1470-1473.	9.4	564
261	Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma. <i>Cancer Research</i> , 2013, 73, 897-907.	0.4	161
262	Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 714-723.	0.9	125
263	The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butyl nitron (OKN007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGF β 1/SMAD2 and Hedgehog/GLI1 signaling. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 225-236.	1.5	50
264	Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing. <i>Journal of Hepatology</i> , 2013, 58, 1042-1044.	1.8	5
265	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. <i>Human Pathology</i> , 2013, 44, 1216-1222.	1.1	127
266	Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk. <i>Hepatology</i> , 2013, 57, 648-655.	3.6	120
267	Identification of Rtl1, a Retrotransposon-Derived Imprinted Gene, as a Novel Driver of Hepatocarcinogenesis. <i>PLoS Genetics</i> , 2013, 9, e1003441.	1.5	76
268	Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. <i>Cancer Cytopathology</i> , 2013, 121, 708-717.	1.4	66
269	Activation of the Transcription Factor GLI1 by WNT Signaling Underlies the Role of SULFATASE 2 as a Regulator of Tissue Regeneration. <i>Journal of Biological Chemistry</i> , 2013, 288, 21389-21398.	1.6	31
270	Reply. <i>Hepatology</i> , 2013, 58, 1863-1863.	3.6	0

#	ARTICLE	IF	CITATIONS
271	Molecular Bioluminescence Imaging as a Noninvasive Tool for Monitoring Tumor Growth and Therapeutic Response to MRI-Guided Laser Ablation in a Rat Model of Hepatocellular Carcinoma. <i>Investigative Radiology</i> , 2013, 48, 413-421.	3.5	21
272	Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2013, 04, 1000145.	0.4	15
273	Biliary Tract Cancers in Olmsted County, Minnesota, 1976-2008. <i>American Journal of Gastroenterology</i> , 2012, 107, 1256-1262.	0.2	68
274	Metallothionein MT1M is a tumor suppressor of human hepatocellular carcinomas. <i>Carcinogenesis</i> , 2012, 33, 2568-2577.	1.3	65
275	Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment. <i>Liver Cancer</i> , 2012, 1, 226-237.	4.2	50
276	Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. <i>Gastroenterology</i> , 2012, 142, 1021-1031.e15.	0.6	443
277	Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo. <i>Breast Cancer Research</i> , 2012, 14, R43.	2.2	15
278	New issues in the pathogenesis of hepatocellular carcinoma: Applying insights from next-generation DNA sequencing technologies to improve therapy for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 200-205.	1.0	1
279	Viral Hepatitis Among Somali Immigrants in Minnesota: Association of Hepatitis C With Hepatocellular Carcinoma. <i>Mayo Clinic Proceedings</i> , 2012, 87, 17-24.	1.4	36
280	Hepatocellular Carcinoma in Olmsted County, Minnesota, 1976-2008. <i>Mayo Clinic Proceedings</i> , 2012, 87, 9-16.	1.4	39
281	Development and Preliminary Testing of a Translational Model of Hepatocellular Carcinoma for MR Imaging and Interventional Oncologic Investigations. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 385-395.	0.2	22
282	Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. <i>Journal of Hepatology</i> , 2012, 56, 176-183.	1.8	41
283	Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 486-487.	1.8	8
284	Comparison of Methods to Detect Neoplasia in Patients Undergoing Endoscopic Ultrasound-Guided Fine-Needle Aspiration. <i>Gastroenterology</i> , 2012, 142, 1112-1121.e2.	0.6	41
285	Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. <i>Human Pathology</i> , 2012, 43, 1552-1558.	1.1	211
286	Liver and Biliary Tract Tumors. , 2012, , 1297-1303.		1
287	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 614-621.	3.6	83
288	Silencing of miR-370 in Human Cholangiocarcinoma by Allelic Loss and Interleukin-6 Induced Maternal to Paternal Epigenotype Switch. <i>PLoS ONE</i> , 2012, 7, e45606.	1.1	48

#	ARTICLE	IF	CITATIONS
289	The Transcription Factor GLI1 Mediates TGF β ²¹ Driven EMT in Hepatocellular Carcinoma via a SNAI1-Dependent Mechanism. <i>PLoS ONE</i> , 2012, 7, e49581.	1.1	68
290	Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 617-623.e1.	2.4	116
291	Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 64-70.	2.4	216
292	Genes Associated with Recurrence of Hepatocellular Carcinoma: Integrated Analysis by Gene Expression and Methylation Profiling. <i>Journal of Korean Medical Science</i> , 2011, 26, 1428.	1.1	37
293	The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. <i>Seminars in Cancer Biology</i> , 2011, 21, 35-43.	4.3	322
294	Rare Distant Skeletal Muscle Metastasis from Hilar Cholangiocarcinoma: Report of a Case. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 171-173.	0.6	7
295	Telomerase mutation: A genetic risk factor for cirrhosis. <i>Hepatology</i> , 2011, 53, 1430-1432.	3.6	18
296	Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. <i>Hepatology</i> , 2011, 54, 940-948.	3.6	172
297	Occult hepatitis B virus infection: Bit player or role player?. <i>Hepatology</i> , 2011, 54, 760-763.	3.6	10
298	Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor phenotypes, and survival. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 122-135.	1.5	55
299	Hedgehog Inhibition Promotes a Switch from Type II to Type I Cell Death Receptor Signaling in Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e18330.	1.1	27
300	Using Mechanistic Models to Simulate Comparative Effectiveness Trials of Therapy and to Estimate Long-term Outcomes in HIV Care. <i>Medical Care</i> , 2010, 48, S90-S95.	1.1	9
301	Hepatic adenomas associated with anti-epileptic drugs: a case series and imaging review. <i>Abdominal Imaging</i> , 2010, 35, 208-211.	2.0	5
302	The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. <i>Hepatology</i> , 2010, 52, 1680-1689.	3.6	96
303	Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. <i>Liver International</i> , 2010, 30, 1522-1528.	1.9	28
304	Evaluation of a Focal Lesion in the Liver. <i>Gastroenterology</i> , 2010, 139, e10-e11.	0.6	4
305	A Necrotic Liver Mass. <i>Gastroenterology</i> , 2010, 139, e6-e7.	0.6	6
306	Comparison of KRAS Mutation Analysis and FISH for Detecting Pancreatobiliary Tract Cancer in Cytology Specimens Collected During Endoscopic Retrograde Cholangiopancreatography. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 780-786.	1.2	72

#	ARTICLE	IF	CITATIONS
307	Hepatocellular carcinoma: a global view. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 448-458.	8.2	1,159
308	miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 120-125.	1.0	133
309	Epidemiology and Management of Hepatocellular Carcinoma. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 899-919.	1.9	166
310	Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. <i>Gut and Liver</i> , 2010, 4, 537-542.	1.4	4
311	Liver transplantation after radioembolization in a patient with unresectable HCC. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 679-683.	8.2	12
312	Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. <i>Journal of Hepatology</i> , 2009, 50, 1112-1121.	1.8	32
313	A Multivariable Model Using Advanced Cytologic Methods for the Evaluation of Indeterminate Pancreatobiliary Strictures. <i>Gastroenterology</i> , 2009, 136, 2180-2186.	0.6	176
314	Î±-Fetoprotein, Des-Î³ Carboxyprothrombin, and Lectin-Bound Î±-Fetoprotein in Early Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 137, 110-118.	0.6	644
315	A new, effective and high-yield approach for identifying liver tumor suppressors. <i>Genome Medicine</i> , 2009, 1, 26.	3.6	1
316	PDGFRÎ±: a new therapeutic target in the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 443-454.	1.5	42
317	Hepatic Vein Tumor Thrombus as a Risk Factor for Excessive Pulmonary Deposition of Microspheres during TheraSphere Therapy for Unresectable Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1460-1463.	0.2	21
318	Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. <i>Liver International</i> , 2008, 28, 12-27.	1.9	47
319	Diagnosis and management of cholangiocarcinoma. <i>Current Gastroenterology Reports</i> , 2008, 10, 43-52.	1.1	30
320	The Tumor Suppressor Function of Human Sulfatase 1 (SULF1) in Carcinogenesis. <i>Journal of Gastrointestinal Cancer</i> , 2008, 39, 149-158.	0.6	84
321	Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 1211-1222.	3.6	170
322	The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. <i>Journal of Hepatology</i> , 2008, 49, 373-383.	1.8	44
323	Clinical Challenges and Images in GI. <i>Gastroenterology</i> , 2008, 135, 18-328.	0.6	1
324	Sorafenib in Liver Cancer â€” Just the Beginning. <i>New England Journal of Medicine</i> , 2008, 359, 420-422.	13.9	103

#	ARTICLE	IF	CITATIONS
325	Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival. <i>Clinical Cancer Research</i> , 2008, 14, 419-427.	3.2	486
326	Treatment options for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 81-92.	1.4	29
327	Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. <i>Future Oncology</i> , 2008, 4, 803-814.	1.1	49
328	Correlating Routine Cytology, Quantitative Nuclear Morphometry by Digital Image Analysis, and Genetic Alterations by Fluorescence In Situ Hybridization to Assess the Sensitivity of Cytology for Detecting Pancreatobiliary Tract Malignancy. <i>American Journal of Clinical Pathology</i> , 2007, 128, 272-279.	0.4	70
329	Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation. <i>Clinical Cancer Research</i> , 2007, 13, 1140-1148.	3.2	75
330	An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. <i>Human Pathology</i> , 2007, 38, 491-499.	1.1	52
331	Hypothyroidism: A Possible Risk Factor for Liver Cancer in Patients With No Known Underlying Cause of Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 118-123.	2.4	90
332	Factors Associated With Increased Survival After Photodynamic Therapy for Cholangiocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 743-748.	2.4	68
333	Casting a Wider Net: Improving Access to Medical Literature in Developing Countries. <i>Mayo Clinic Proceedings</i> , 2007, 82, 846-848.	1.4	1
334	Treatment Options for Hepatobiliary and Pancreatic Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 628-637.	1.4	58
335	The Utility of Lens Culinaris Agglutinin-Reactive $\hat{\pm}$ -Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: Evaluation in a United States Referral Population. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 394-402.	2.4	106
336	Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 483-490.	0.5	39
337	Advanced Cytologic Techniques for the Detection of Malignant Pancreatobiliary Strictures. <i>Gastroenterology</i> , 2006, 131, 1064-1072.	0.6	297
338	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2378-2387.	1.9	102
339	SULF1 Inhibits Tumor Growth and Potentiates the Effects of Histone Deacetylase Inhibitors in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2006, 130, 2130-2144.	0.6	64
340	Emerging drugs for hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 469-487.	1.0	34
341	A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. <i>Nature Medicine</i> , 2006, 12, 410-416.	15.2	889
342	MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 159-162.	1.2	14

#	ARTICLE	IF	CITATIONS
343	Fiducial markers for MR histological correlation in ex vivo or short-term in vivo animal experiments: A screening study. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 23, 50-59.	1.9	14
344	Study of Shear Wave Displacement Change Measured by 1D MRE During Focused Ultrasound Treatment: Preliminary Study. <i>AIP Conference Proceedings</i> , 2006, , .	0.3	7
345	Magnetic Resonance Elastography Assessment of Focused Ultrasound Surgery in Cancer Models: A Pilot Study. , 2006, , .		0
346	A Clinically Based Discrete-Event Simulation of End-Stage Liver Disease and the Organ Allocation Process. <i>Medical Decision Making</i> , 2005, 25, 199-209.	1.2	98
347	Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets. <i>Seminars in Liver Disease</i> , 2005, 25, 212-225.	1.8	261
348	The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 42, 760-777.	1.8	180
349	The Optimal Timing of Living-Donor Liver Transplantation. <i>Management Science</i> , 2004, 50, 1420-1430.	2.4	162
350	A Comparison of Routine Cytology and Fluorescence in situ Hybridization for the Detection of Malignant Bile Duct Strictures. <i>American Journal of Gastroenterology</i> , 2004, 99, 1675-1681.	0.2	338
351	HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. <i>Oncogene</i> , 2004, 23, 1439-1447.	2.6	132
352	Parkigene alterations in hepatocellular carcinoma. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 85-96.	1.5	105
353	Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS database. <i>Liver Transplantation</i> , 2004, 10, 886-897.	1.3	338
354	hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. <i>Gastroenterology</i> , 2004, 126, 231-248.	0.6	135
355	Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer. <i>Journal of Biological Chemistry</i> , 2003, 278, 23107-23117.	1.6	215
356	The Cost-Effectiveness of Sildenafil. <i>Annals of Internal Medicine</i> , 2000, 132, 933.	2.0	62
357	The Characterization of the Common Fragile Site FRA16D and Its Involvement in Multiple Myeloma Translocations. <i>Genomics</i> , 2000, 69, 37-46.	1.3	87
358	Antiviral Therapies for Herpes Zoster Infections. <i>Pharmacoeconomics</i> , 2000, 18, 95-104.	1.7	29
359	Cathepsins as effector proteases in hepatocyte apoptosis. <i>Cell Biochemistry and Biophysics</i> , 1999, 30, 71-88.	0.9	99
360	Image of the month. <i>Gastroenterology</i> , 1998, 114, 432.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox*. <i>Pharmacoeconomics</i> , 1998, 13, 645-651.	1.7	5
362	MELAS- and kearns-sayre-type with myopathy and autoimmune polyendocrinopathy. <i>Annals of Neurology</i> , 1996, 39, 761-766.	2.8	57
363	cDNA and amino-acid sequences and organization of the gene encoding the B β subunit of fibrinogen from <i>Xenopus laevis</i> . <i>Gene</i> , 1995, 160, 223-228.	1.0	6
364	Transcriptional regulation of the <i>Xenopus laevis</i> B β fibrinogen subunit gene by glucocorticoids and hepatocyte nuclear factor 1: Analysis by transfection into primary liver cells. <i>Biochemistry</i> , 1993, 32, 11627-11637.	1.2	13
365	Molecular cloning of cDNA for the B β subunit of <i>Xenopus</i> fibrinogen, the product of a coordinately-regulated gene family. <i>Molecular and Cellular Endocrinology</i> , 1991, 75, 111-121.	1.6	6